^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    JNJ-63709178

    i
    Other names: JNJ-63709178, CD123 x CD3 DuoBody, JNJ 63709178, CD123-CD3 DuoBody protein, CNTO 9958, JNJ-9178
    Associations

    News

    Trials
    Company:
    Genmab, J&J
    Drug class:
    CD3 agonist, CD123 inhibitor
    Related drugs:
    Associations

    News

    Trials
    almost2years
    First-in-Human Study of JNJ-63709178, a CD123/CD3 Targeting Antibody, in Relapsed/Refractory Acute Myeloid Leukemia. (PubMed, Clin Transl Sci)
    Minimal clinical activity was observed across all cohorts. IV and SC dosing of JNJ-63709178 was associated with suboptimal drug exposure, unfavorable safety profiles, limited clinical activity, and inability to identify a recommended Phase 2 dose.
    P1 data • Journal
    |
    CD123 (Interleukin 3 Receptor Subunit Alpha)
    |
    JNJ-63709178
    over3years
    Dose Escalation Study of JNJ-63709178, a Humanized CD123 x CD3 DuoBody in Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML) (clinicaltrials.gov)
    P1, N=62, Completed, Janssen Research & Development, LLC | Recruiting --> Completed | N=120 --> 62 | Trial completion date: Oct 2022 --> Mar 2021 | Trial primary completion date: May 2022 --> Mar 2021
    Clinical • Trial completion • Enrollment change • Trial completion date • Trial primary completion date
    |
    CD123 (Interleukin 3 Receptor Subunit Alpha)
    |
    JNJ-63709178
    4years
    Dose Escalation Study of JNJ-63709178, a Humanized CD123 x CD3 DuoBody in Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML) (clinicaltrials.gov)
    P1, N=120, Recruiting, Janssen Research & Development, LLC | Trial primary completion date: Oct 2020 --> May 2022
    Clinical • Trial primary completion date
    |
    CD123 (Interleukin 3 Receptor Subunit Alpha)
    |
    JNJ-63709178
    almost5years
    Dose Escalation Study of JNJ-63709178, a Humanized CD123 x CD3 DuoBody in Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML) (clinicaltrials.gov)
    P1, N=120, Recruiting, Janssen Research & Development, LLC | Trial completion date: May 2022 --> Oct 2022
    Clinical • Trial completion date
    |
    CD123 (Interleukin 3 Receptor Subunit Alpha)
    |
    JNJ-63709178
    5years
    Dose Escalation Study of JNJ-63709178, a Humanized CD123 x CD3 DuoBody in Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML) (clinicaltrials.gov)
    P1, N=120, Recruiting, Janssen Research & Development, LLC | N=60 --> 120 | Trial completion date: Oct 2021 --> May 2022
    Clinical • Enrollment change • Trial completion date
    |
    CD123 (Interleukin 3 Receptor Subunit Alpha)
    |
    JNJ-63709178
    6years
    Dose Escalation Study of JNJ-63709178, a Humanized CD123 x CD3 DuoBody in Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML) (clinicaltrials.gov)
    P1, N=60, Recruiting, Janssen Research & Development, LLC | Trial completion date: Apr 2021 --> Aug 2021 | Suspended --> Recruiting
    Clinical • Enrollment open • Trial completion date
    |
    CD123 (Interleukin 3 Receptor Subunit Alpha)
    |
    JNJ-63709178
    over6years
    Dose Escalation Study of JNJ-63709178, a Humanized CD123 x CD3 DuoBody in Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML) (clinicaltrials.gov)
    P1, N=60, Suspended, Janssen Research & Development, LLC | Trial completion date: Oct 2020 --> Apr 2021
    Trial completion date
    |
    CD123 (Interleukin 3 Receptor Subunit Alpha)
    |
    CD123 expression
    |
    JNJ-63709178